Single-Cell Analysis – News and Features

A new small molecule could alleviate pain for sickle cell disease patients who don't respond to hydroxyurea.

Researchers have identified a previously unknown cause of long COVID within the lungs. Their study suggests that a treatment previously used for rheumatoid arthritis might be effective in halting the chronic inflammation associated with the condition.

ACE, a new DNA-powered signal amplification technology, dramatically increases sensitivity of mass cytometry, opening new windows on many biological and pathological processes.

Merkel cell carcinoma is a rare but highly aggressive form of skin cancer known for its rapid growth and tendency to metastasize. Despite the promise of immune checkpoint blockade therapy, nearly half of patients do not respond to this treatment.

As part of a breast cancer diagnosis, pathologists take cells from a biopsy and check them under a microscope. Most cancerous cells form roundish clumps, known as no special type, or invasive ductal carcinoma (IDC).

Combining different types of omics data offers tantalizing opportunities to gain a more comprehensive overview of cellular systems. This article will explore some of the latest advances in multiomics analysis that have opened up new frontiers in cell biology.

Research published in Nature reveals a new pain control pathway from the cortex to the cerebellum crucial to placebo analgesia – when the expectation of pain relief leads to pain alleviation without a therapeutic intervention, such as with a drug.

Researchers have found that DNA sequences originating from ancient viral infections can play a critical role in helping cancer to survive and thrive. The researchers suggest that silencing these sequences could help to improve cancer treatments.

Investigators have uncovered new details about the role of a protein called interferon regulatory factor (IRF1) in cancer progression and treatment response, offering new insight that can potentially help improve the effectiveness of cancer immunotherapy.

KRAS inhibitors are showing initial promise in clinical trials, but many tumors quickly develop resistance to the treatment. Now, researchers have discovered a new mechanism of resistance that suggests an opportunity to make the treatment more effective.